FDA Approved: LIBTAYO — Original Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA granted original approval for LIBTAYO (cemiplimab-rwlc) from Regeneron Pharmaceuticals for cutaneous squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Libtayo (cemiplimab)

Snippet

ORIG AP for LIBTAYO (CEMIPLIMAB-RWLC)